FOUGERA PHARMS
PharmaFOUGERA PHARMS is a pharmaceutical company focused on Dermatology, Ophthalmology, Oncology.
FOUGERA PHARMS at a Glance
- Fast trial execution (15 months median completion)
FOUGERA PHARMS's Key Drugs
FOUGERA PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
FOUGERA PHARMS's Recent FDA Approvals
New NDA/BLA approvals for FOUGERA PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
FOUGERA PHARMS's Therapeutic Areas
FOUGERA PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Ophthalmology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
FOUGERA PHARMS's Top Competitors
FOUGERA PHARMS's closest competitors by therapeutic-area and drug-target overlap include Baxter, Bayer, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
FOUGERA PHARMS Pipeline Snapshot
Active clinical trials for FOUGERA PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 5/9 completed
- • Speed: 15 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1953-04-09
- Latest
- 2026-02-24
- Applications
- 105
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges